Ad
Wednesday, 3 January 2018
Momenta, Mylan plan trial of biosimilar to Regeneron eye drug
(Reuters) - Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment